Replies to post #127925 on PharmaCyte Biotech Inc (PMCB)

[$Pistol Pete$]

So why gerald crabtree get paid less than the greedy CEO? What is that telling you? They are all for money but not the 20 years old technology. This is just a selling shares machine and nothing new

[DragonBear]

i wouldnt talk for the fda even though u may be right

pancreatic cancer has a 93% death rate,its time for a new approach ,targeted chemo

But delivering locally is not a new approach. nab-paclitaxel or Abraxane is encapsulated delivery. So is Nanoliposomal Irinotecan in 2nd line. The direct match is RenovoRX's dual-balloon infusion catheter. Where ANY chemo drug can be used, and there's no requirement for any magic cells. They are in Phase 3 using Gemcitabine in 1st line patients.

using stem cells right at the source with a 3rd of the side effects

No, stem cells are not involved within the CIABs. Neither has it been proven side effects will be minimal in 2nd line patients. Where their bone marrow is already in a fragile condition due to prior Chemo, and the cancer. Lohr found fewer side effects in "first line" patients at 1 gm/m2 dosage. At 2 gm/m2 increased but not serious side effects. It is known in "second line" patients 1.4 gms/m2 can cause neurological side effects. Ifosfamide at any dose can cause hemorrhagic cystitis if Mensa is not given.

Ifosfamide is extremely toxic. That's why first cyclophosphamide was invented, and more recently Glufosfamide. The later not requiring activation outside the cancerous cell.

on the other hand the esteemed manuel hildago has agreed to conduct the trial

He'll be paid the going fee to do so.

also gerald crabtree although a little older like all us has tons of experience dealing with the fda

As a project manager with a major Pharma.

did he not play a big part in getting abraxine approved by the fda

No, that was Von Hoff who left years ago.

also the cells have passed all fda req tests so far

Big whoop. It's actually quite pitiful. It took 5 yrs just to start on pre-clinical, and 3 yrs later, still not complete.